132 related articles for article (PubMed ID: 33710118)
1. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
Ansari SH; Hussain Z; Zohaib M; Parveen S; Kaleem B; Qamar H; Adil O; Khan MT; Shamsi TS
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e77-e83. PubMed ID: 33710118
[TBL] [Abstract][Full Text] [Related]
2. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
3. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
4. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
5. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
8. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Gγ-globin promoter -158 (C>T) XmnI polymorphism in patients with homozygous/compound heterozygous beta thalassaemia.
Ali N; Ayyub M; Khan SA; Ahmed S; Abbas K; Malik HS; Tashfeen S
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):10-5. PubMed ID: 25591326
[TBL] [Abstract][Full Text] [Related]
11. An Aγ-globin G->A gene polymorphism associated with β
Breveglieri G; Bianchi N; Cosenza LC; Gamberini MR; Chiavilli F; Zuccato C; Montagner G; Borgatti M; Lampronti I; Finotti A; Gambari R
BMC Med Genet; 2017 Aug; 18(1):93. PubMed ID: 28851297
[TBL] [Abstract][Full Text] [Related]
12. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
Yang K; Wu Y; Ma Y; Xiao J; Zhou Y; Yin X
Blood Cells Mol Dis; 2020 Sep; 84():102442. PubMed ID: 32387854
[TBL] [Abstract][Full Text] [Related]
13. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Ansari SH; Shamsi TS; Munzir S; Khan MT; Erum S; Perveen K; Farzana T; Ashraf M; Mehboob T; Moinuddin M
J Pediatr Hematol Oncol; 2013 May; 35(4):e153-6. PubMed ID: 23389500
[TBL] [Abstract][Full Text] [Related]
14. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
16. Modulatory effect of single nucleotide polymorphism in Xmn1, BCL11A and HBS1L-MYB loci on foetal haemoglobin levels in β-thalassemia major and Intermedia patients.
Bashir S; Mahmood S; Mohsin S; Tabassum I; Ghafoor M; Sajjad O
J Pak Med Assoc; 2021 May; 71(5):1394-1398. PubMed ID: 34091621
[TBL] [Abstract][Full Text] [Related]
17. The molecular characterization of Beta globin gene in thalassemia patients reveals rare and a novel mutations in Pakistani population.
Yasmeen H; Toma S; Killeen N; Hasnain S; Foroni L
Eur J Med Genet; 2016 Aug; 59(8):355-62. PubMed ID: 27263053
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic variations influencing fetal hemoglobin levels: association study in beta-thalassemia carriers and in normal individuals of Portuguese origin.
Pereira C; Relvas L; Bento C; Abade A; Ribeiro ML; Manco L
Blood Cells Mol Dis; 2015 Apr; 54(4):315-20. PubMed ID: 25842369
[TBL] [Abstract][Full Text] [Related]
19. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
20. A Population-Oriented Genetic Scoring System to Predict Phenotype: A Pathway to Personalized Medicine in Iraqis With β-Thalassemia.
Al-Allawi N; Atroshi SD; Sadullah RK; Eissa AA; Kriegshäuser G; Al-Zebari S; Qadir S; Khalil D; Oberkanins C
Hemoglobin; 2024 Mar; 48(2):94-100. PubMed ID: 38390736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
